These findings suggest that in vivo, the ASIP-expressing cells exhibited slower growth than the B16-GFP cells, which could partially explain why mice bearing B16-ASIP-mChy tumors showed increased survival, although it does not explain why the B16-ASIP-mChy and a 1:1 mix groups reached endpoint criteria with higher tumor loads. This evidence concerns the gene ASIP and neoplasm.